Abstract
3,4-Methylenedioxymethamphetamine (MDMA or ecstasy) is a worldwide illegally used amphetamine-derived designer drug known to be hepatotoxic to humans. Jaundice, hepatomegaly, centrilobular necrosis, hepatitis and fibrosis represent some of the adverse effects caused by MDMA in the liver. Although there is irrefutable evidence of MDMA-induced hepatocellular damage, the mechanisms responsible for that toxicity remain to be thoroughly clarified. One well thought-of mechanism imply MDMA metabolism in the liver into reactive metabolites as responsible for the MDMA-elicited hepatotoxicity. However, other factors, including MDMA-induced hyperthermia, the increase in neurotransmitters efflux, the oxidation of biogenic amines, polydrug abuse pattern, and environmental features accompanying illicit MDMA use, may increase the risk for liver complications. Liver damage patterns of MDMA in animals and humans and current research on the mechanisms underlying the hepatotoxic effects of MDMA will be highlighted in this review.
Keywords: Ecstasy, MDMA, hepatotoxicity, liver damage, mechanisms
Current Pharmaceutical Biotechnology
Title: Mechanisms Underlying the Hepatotoxic Effects of Ecstasy
Volume: 11 Issue: 5
Author(s): Marcia Carvalho, Helena Pontes, Fernando Remiao, Maria L. Bastos and Felix Carvalho
Affiliation:
Keywords: Ecstasy, MDMA, hepatotoxicity, liver damage, mechanisms
Abstract: 3,4-Methylenedioxymethamphetamine (MDMA or ecstasy) is a worldwide illegally used amphetamine-derived designer drug known to be hepatotoxic to humans. Jaundice, hepatomegaly, centrilobular necrosis, hepatitis and fibrosis represent some of the adverse effects caused by MDMA in the liver. Although there is irrefutable evidence of MDMA-induced hepatocellular damage, the mechanisms responsible for that toxicity remain to be thoroughly clarified. One well thought-of mechanism imply MDMA metabolism in the liver into reactive metabolites as responsible for the MDMA-elicited hepatotoxicity. However, other factors, including MDMA-induced hyperthermia, the increase in neurotransmitters efflux, the oxidation of biogenic amines, polydrug abuse pattern, and environmental features accompanying illicit MDMA use, may increase the risk for liver complications. Liver damage patterns of MDMA in animals and humans and current research on the mechanisms underlying the hepatotoxic effects of MDMA will be highlighted in this review.
Export Options
About this article
Cite this article as:
Carvalho Marcia, Pontes Helena, Remiao Fernando, L. Bastos Maria and Carvalho Felix, Mechanisms Underlying the Hepatotoxic Effects of Ecstasy, Current Pharmaceutical Biotechnology 2010; 11 (5) . https://dx.doi.org/10.2174/138920110791591535
DOI https://dx.doi.org/10.2174/138920110791591535 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Pharmacologic Management of Pediatric Heart Failure in Congenital Heart Disease
Current Vascular Pharmacology Drug Therapy for Behavioral and Psychological Symptoms of Dementia
Current Neuropharmacology Recent Insights into the Role of Prostanoids in Atherosclerotic Vascular Disease
Current Vascular Pharmacology Torasemide for the Treatment of Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets The Effects of Sevoflurane or Remifentanil on the Stress Response to Surgical Stimulus
Current Pharmaceutical Design Relative Survival Benefit and Morbidity with Fluids in Severe Sepsis - A Network Meta-Analysis of Alternative Therapies
Current Drug Safety Drugs in Newborn Resuscitation: The More We Learn the Least We Use
Current Medicinal Chemistry Nebulizer Therapy in Pulmonology: Review of the Literature
Current Respiratory Medicine Reviews Neuroprotection by Diazoxide in Animal Models for Cerebrovascular Disorders
Vascular Disease Prevention (Discontinued) NO News is not Necessarily Good News in Cancer
Current Cancer Drug Targets Fetal Undernutrition and the Programming of Blood Pressure
Current Nutrition & Food Science Potassium Channel Openers and Improvement of Toxic Stress: Do they have Role in the Management of Inflammatory Bowel Disease?
Inflammation & Allergy - Drug Targets (Discontinued) Industrial Chemicals and Acute Lung injury with a Focus on Exposure Scenarios
Current Respiratory Medicine Reviews Treating Hypertension in the Elderly: Common Problems and Solutions
Current Hypertension Reviews Editorial: [Hot Topic: Antidotes and Rescue Therapies]
Current Pharmaceutical Biotechnology Antiviral Drugs that Target Cellular Proteins May Play Major Roles in Combating HIV Resistance
Current Pharmaceutical Design Design, Synthesis and Antimicrobial Properties of Novel 3,3a,4,5,6,7- Hexahydroindazole and Arylthiazolylpyrazoline Derivatives
Medicinal Chemistry Antibacterial Effects of Carbon Monoxide
Current Pharmaceutical Biotechnology Classical and New Renin-Angiotensin Signalling in Atherosclerosis
Current Signal Transduction Therapy Elucidation of Abnormal Extracellular Regulated Kinase (ERK) Signaling and Associations with Syndromic and Non-syndromic Autism
Current Drug Targets